What have we learnt about asthma control from trials of budesonide/formoterol as maintenance and reliever?. Issue 8 (31st March 2020)

• Record Type: Journal Article
• Authors: Jenkins, Christine R.; Bateman, Eric D.; Sears, Malcolm R.; O'Byrne, Paul M.
• Is Part Of: Respirology. Volume 25:Issue 8(2020)
• Page Start: 804
• Page End: 815
• Publication Date: 2020-03-31
• Subjects: adherence -- asthma control -- corticosteroid exposure -- exacerbations -- maintenance and reliever; Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Periodicals; 612.2
• DOI: 10.1111/resp.13804
• Languages: English
• ISSNs: 1323-7799

Abstract

ABSTRACT: Despite improvements in medications, devices and understanding of the disease, about half of all asthma patients worldwide remain inadequately controlled, suggesting the need for a new approach to asthma management. Poor adherence to prescribed maintenance therapy and over‐reliance on SABA reliever medication is a common cause of inadequate control. This article reviews published data from 6‐ to 12‐month, double‐blind, RCT and open‐label real‐world studies involving budesonide/formoterol maintenance and reliever therapy (MART) and relevant comparator approaches to asthma management, and considers how these compare in achieving the treatment goals described in guidelines. The data confirm that patients with asthma treated with budesonide/formoterol MART achieved the same or better asthma symptom control compared with ICS/LABA plus SABA regimens at similar or higher ICS doses, with consistently lower rates of exacerbations and considerably lower annual requirement for oral corticosteroids. These findings have been confirmed across a range of severities of persistent asthma. With the MART approach, maintenance dosing ensures coverage for day‐to‐day control, and the use of a reliever with anti‐inflammatory properties (budesonide/formoterol) provides extra doses of ICS as soon as symptoms prompt the use of reliever, resulting in a 40–50% reduction of exacerbations compared with an ICS‐based treatment approach plus as‐needed SABA as reliever. As‐needed, budesonide/formoterol has also recently been shown to be more effective as a reliever in mild asthma than SABA alone, reducing exacerbations by up to 64% in the SYGMA studies. Abstract : See related Editorial